California is the biggest state so far to seek to pull back the curtain on pharmacy-benefits managers, as the industry aggressively tries to thwart a wider push for transparency.
For the first two decades that Jessica Price had diabetes, she never worried about the price of her insulin and supplies, since her mother’s insurance covered the cost.
“On June 27th at 5:20 I received a phone call from his girlfriend saying that she had found him dead in his apartment.”
As the debate over the future of health care coverage moves in fits and starts, it may seem like any improvements in health care coverage are equally stalled.
Across the board, drug prices are soaring.
Scott Gottlieb, head of the Food and Drug Administration, wasted no time in his opening remarks at a forum last week on high drug prices.
The cost of insulin has more than tripled in the last decade, and U.S. Sen. Amy Klobuchar says it’s financially squeezing people with diabetes who rely on the drug to regulate their blood sugar.
Republican healthcare bills in the House and Senate have people concerned about whether they’ll be left uninsured — or underinsured.
Robert Newton has been taking insulin for years to keep his diabetes in check, but with the medication now costing him $500 a month, there are times when he has no choice but to ration his supply and take less than he should.
I applaud the push to rein in insulin prices. In Nevada, we are way ahead of Washington when it comes to sending a message to Big Pharma that enough is enough.
David Hernandez, a 44-year-old restaurant worker and Type 1 diabetic, didn’t have insurance from 2011 through 2014 and often couldn’t afford insulin—a workhorse drug whose list price has risen more than 270 percent over the past decade.
Egyptian medical texts dated around 550 B.C. contain the earliest known descriptions of diabetes.